万泰生物(603392.SH)：九价人乳头瘤病毒疫苗（大肠埃希菌）首次获得批签发证明

Core Viewpoint - The company WanTai BioPharma (603392.SH) has received the biological product batch release certificate for its nine-valent HPV vaccine, marking its official market launch, which is expected to enhance its revenue and profit growth potential [1] Group 1 - The nine-valent HPV vaccine produced by the company's wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has been approved for market release [1] - The launch of the nine-valent HPV vaccine will enrich and optimize the company's product lineup, providing a new revenue and profit growth point [1] - The combination of the nine-valent HPV vaccine with the existing bivalent HPV vaccine will create a differentiated and competitive product matrix, catering to diverse market segments and consumer needs [1]